)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Elicio Therapeutics
Elicio Therapeutics (ELTX) investor relations material
Elicio Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
Focused on developing next-generation immunotherapies for mKRAS-positive cancers, with lead candidate ELI-002 7P in clinical trials targeting pancreatic, colorectal, and lung cancers.
Multiple complete responses observed with ELI-002 7P and checkpoint inhibition in metastatic mKRAS pancreatic cancer, supporting a planned Phase 1 combination study in Q4 2026.
Phase 2 AMPLIFY-7P trial did not meet its primary endpoint but showed early disease-free survival benefit and favorable safety in subgroups, informing a refined Phase 3 strategy.
Memorial Sloan Kettering Cancer Center initiated a Phase 1 trial of ELI-002 7P plus chemotherapy and checkpoint inhibition in neoadjuvant pancreatic cancer.
Substantial doubt exists about ability to continue as a going concern, with cash runway into Q1 2027 and recent capital raises in July 2026.
Financial highlights
Net loss of $20.0 million for the six months ended June 30, 2026, compared to $21.8 million for the same period in 2025.
Net loss for Q2 2026 was $8.2 million ($0.43 per share), improved from $10.6 million ($0.66 per share) in Q2 2025.
Research and development expenses decreased to $13.6 million for H1 2026; Q2 2026 R&D expense was $6.8 million.
General and administrative expenses increased to $7.5 million for H1 2026; Q2 2026 G&A expense was $3.6 million.
Cash and cash equivalents were $23.5 million as of June 30, 2026; aggregate net proceeds of $24.4 million year-to-date through at-the-market and direct offerings.
Outlook and guidance
Cash on hand expected to fund operations into Q1 2027; additional capital required for continued development and to initiate planned clinical trials.
Phase 1 combination study in metastatic PDAC planned for Q4 2026; Phase 3 adjuvant PDAC trial contingent on further capital raise.
Ongoing evaluation of Phase 2 subgroups to inform Phase 3 development in adjuvant PDAC.
Expenses expected to increase as pipeline advances and company expands operations.
RO subgroup analysis impact on Phase 3 design
Rationale for ELI-002 7P and RAS inhibitor combo
Funding strategy beyond the Q1 2027 cash runway
Phase 3 strategy adjustments after AMPLIFY-7P
Financing hurdles for the adjuvant Phase 3 trial
Rationale for the ELI-002 7P combination study
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Elicio Therapeutics
- Durable complete responses observed after ELI-002 7P and checkpoint inhibition in metastatic PDAC.ELTX
Corporate presentation - Rare, durable complete responses after ELI-002 and checkpoint inhibition prompt Phase 1 study.ELTXKOL event
- ELI-002 7P delivers robust, durable immune responses in mKRAS cancers with strong clinical potential.ELTXCorporate presentation
- Post-hoc analysis shows ELI-002 7P improves DFS in RO resected patients, informing Phase 3 plans.ELTXStudy update
- ELI-002 immunotherapy shows strong immune response and survival benefit; phase II readout due mid-2026.ELTXBank of America Global Healthcare Conference 2026
- Net loss of $11.8M, $14.9M cash, and $13M raised highlight urgent need for new funding by Q4 2026.ELTXQ1 2026
- Biotech seeks $400M for cancer immunotherapy pipeline, with ongoing trials and going concern risk.ELTXRegistration Filing
- Reduced net loss, strong cash position, and key clinical milestones expected in 2026.ELTXQ4 2025
- Phase II data for a lymph node-targeted KRAS immunotherapy show robust T cell responses and safety.ELTXTD Cowen 46th Annual Health Care Conference
Next Elicio Therapeutics earnings date
Q3 202612 Nov, 2026
Elicio Therapeutics
Next Elicio Therapeutics earnings date
Q3 202612 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage